- Defence Therapeutics (DTC) will be collaborating with the Curie Institute to evaluate the efficacy of Accum-T-DM1 ADC
- The Curie Institute has broad expertise in the field of medical and experimental pharmacology with PDX models of cancer
- The efficacy of T-DM1, currently used to treat metastatic HER2-positive breast cancer, is limited due to sub-optimal drug delivery to tumour cells
- Defence Therapeutics is a biotechnology company working on engineering vaccines and ADC products using its proprietary platform
- Defence Therapeutics Inc. (DTC) opened trading at C$7.00 per share
Defence Therapeutics (DTC) will be collaborating with the Curie Institute to evaluate the efficacy of Accum-T-DM1 ADC for the treatment of breast cancer.
The Curie Institute is a worldwide renowned center engaged leader in fundamental and applied scientific research to better serve humankind in fighting illnesses such as cancer. Their scientific team has broad expertise in the field of medical and experimental pharmacology with PDX models of cancer.
T-DM1 (Kadcyla®) is currently used to treat women with metastatic HER2-positive breast cancer. The efficacy of the treatment remains limited due to sub-optimal drug delivery to tumour cells resulting in some treatment resistance, recurrence, and side effects.
The agreement between the Curie Institute and Defence Therapeutics stipulates the following objectives related to breast cancer:
- To perform head-to-head toxicology profile comparisons of T-DM1 versus Accum-T-DM1 in mice.
- Complete a dose-escalation study in mice bearing PDX that are T-DM1 resistant.
- Conduct a complete breast cancer efficacy study on PDX mice undergoing the ADC therapy, including in 3 HER2+ and in 1 triple-negative PDX.
“The AccumTM technology has been very efficient at enhancing protein-/or cell-based vaccination and ADCs potency. This study’s objective of demonstrating enhanced efficacy and the refined treatment regiment of Accum-T-DM1, can lead to an enhanced ADC platform for the AccumTM technology. This serves as a strong foundation for a panoply of other therapeutics endowed with limitations known to impairing their therapeutic potency. AccumTMenhanced efficacy opens up a broad opportunity in the ADC market to address this,” mentioned Sebastien Plouffe, CEO of Defence Therapeutics.
Currently, the T-DM1 regiment is long and tedious. The use of the AccumTM in this context is expected to increase the efficiency as well as to lower the treatment cycle, which would highly lower the side effects triggered by the current ADC therapies.
US Breast Cancer Antibodies immunotherapy Therapeutics Market Offers a US$20 Billion opportunity by 2026 according to Kuick research.
Defence Therapeutics is a biotechnology company focused on engineering vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics’ platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
Defence Therapeutics Inc. (DTC) opened trading at C$7.00 per share.